Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

British Journal of Cancer

Volumn 110, Issue 5, 2014, Pages 1236-1243

  Ilie, M ^a,b   Long, E ^a,b   Hofman, V ^a,b   Selva, E ^b   Bonnetaud, C ^b   Boyer, J ^b   Venissac N ^a,b   Sanfiorenzo, C ^a,b   Ferrua, B ^c   Marquette, C H ^a,b   Mouroux, J ^a,b   Hofman, P ^a,b  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b PASTEUR HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Biomarkers; Circulating endothelial cells; Non small cell lung cancer; Prognosis; Soluble CD146

Indexed keywords

CD146 ANTIGEN; 4',6 DIAMIDINO 2 PHENYLINDOLE; CD45 ANTIGEN; ENDOGLIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURGERY; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CIRCULATING ENDOTHELIAL CELL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN CELL; NON SMALL CELL LUNG CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD146; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895825333     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.11     Document Type: Article

References (63)

1. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, Sampol J, Dignat-George F (2001) Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 98(13): 3677-3684.
2. Bardin N, Blot-Chabaud M, Despoix N, Kebir A, Harhouri K, Arsanto JP, Espinosa L, Perrin P, Robert S, Vely F, Sabatier F, Le Bivic A, Kaplanski G, Sampol J, Dignat-George F (2009) CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 29(5): 746-753.
3. Bardin N, Frances V, Combes V, Sampol J, Dignat-George F (1998) CD146: biosynthesis and production of a soluble form in human cultured endothelial cells. FEBS Lett 421(1): 12-14. (Pubitemid 28068808)
4. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J (1996a) Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 218(1): 210-216.
5. Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, Lesaule G, Sampol J (1996b) S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 48(5): 531-539. (Pubitemid 27007292)
6. Bardin N, Moal V, Anfosso F, Daniel L, Brunet P, Sampol J, Dignat George F (2003) Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 90(5): 915-920. (Pubitemid 37427862)
7. Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F (2006) Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm Bowel Dis 12(1): 16-21. (Pubitemid 43032446)
8. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1): 139-145. (Pubitemid 38139616)
9. Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M (2006) 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 7(10): 829-836. (Pubitemid 44464064)
10. Chu TQ, Ding H, Garfield DH, Gu AQ, Pei J, Du WD, Han BH (2012) Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. J Thorac Oncol 7(12): 1781-1789.
11. D'Souza-Schorey C, Clancy JW (2012) Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26(12): 1287-1299.
12. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66(14): 7341-7347. (Pubitemid 44197717)
13. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8(4): 210-221.
14. Fleitas T, Martinez-Sales V, Gomez-Codina J, Martin M, Reynes G (2010) Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clin Transl Oncol 12(8): 521-525.
15. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94(4): 524-531. (Pubitemid 43289756)
16. Furstenberger G, von Moos R, Senn HJ, Boneberg EM (2005) Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer 93(7): 793-798. (Pubitemid 41486439)
17. Goldstraw P (2009) The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 4(6): 671-673.
18. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8(2): 79-88.
19. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T, Miyaoka E (2005) Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50(2): 227-234. (Pubitemid 41427898)
20. Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti MD, Berenguer C, Lamy E, Vely F, Pisano P, Ouafik L, Sabatier F, Sampol J, Bardin N, Dignat-George F, Blot-Chabaud M (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115(18): 3843-3851.
21. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, Feng J, Yang D, Yan X (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120(11): 2330-2339.
22. Kang Y, Wang F, Feng J, Yang D, Yang X, Yan X (2006) Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res 16(3): 313-318.
23. Kapoor S (2013) CD146 expression and its close relationship to tumor progression in systemic malignancies besides gall bladder carcinomas. Tumour Biol 34(2): 1273-1274.
24. Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4(2): 208-213.
25. Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I (2003) Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 25(2): 77-81. (Pubitemid 36443407)
26. Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86(24): 9891-9895. (Pubitemid 20030740)
27. Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, Zeng HZ (2012) CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 13(5): 6399-6406.
28. Luo Y, Zheng C, Zhang J, Lu D, Zhuang J, Xing S, Feng J, Yang D, Yan X (2012) Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 31(3): 306-321.
29. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, Francois E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F (2012) Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 23(4): 919-927.
30. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97(11): 3658-3661.
31. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2): 452-459. (Pubitemid 44061341)
32. Mancuso P, Rabascio C, Bertolini F (2003) Strategies to investigate circulating endothelial cells in cancer. Pathophysiol Haemost Thromb 33(5-6): 503-506. (Pubitemid 40278732)
33. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F (2001) Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61(11): 4341-4344. (Pubitemid 32685756)
34. Morita R, Sato K, Nakano M, Miura H, Odaka H, Nobori K, Kosaka T, Sano M, Watanabe H, Shioya T, Ito H (2011) Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. J Cancer Res Clin Oncol 137(12): 1849-1857.
35. Mountain CF (2000) The international system for staging lung cancer. Semin Surg Oncol 18(2): 106-115. (Pubitemid 30090451)
36. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F (1999) Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93(9): 2951-2958. (Pubitemid 29200786)
37. Mutunga M, Fulton B, Bullock R, Batchelor A, Gascoigne A, Gillespie JI, Baudouin SV (2001) Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 163(1): 195-200. (Pubitemid 32095270)
38. Narazaki M, Tosato G (2006) Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. J Natl Cancer Inst 98(5): 294-295. (Pubitemid 43338209)
39. Naruke T, Tsuchiya R, Kondo H, Asamura H (2001) Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71(6): 1759-1764. (Pubitemid 32554394)
40. Nowak K, Rafat N, Belle S, Weiss C, Hanusch C, Hohenberger P, Beck G (2010) Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg 37(4): 758-763.
41. Oka S, Uramoto H, Chikaishi Y, Tanaka F (2012) The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung. Anticancer Res 32(3): 861-864.
42. Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, Abdraboh ME, El-Sayyad HI, Rao P, Raj MG (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795(2): 130-136.
43. Pasquier E, Bardin N, De Saint Martin L, Le Martelot MT, Bohec C, Roche S, Mottier D, Dignat-George F (2005) The first assessment of soluble CD146 in women with unexplained pregnancy loss. A new insight? Thromb Haemost 94(6): 1280-1284. (Pubitemid 41819627)
44. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11(3): 261-262. (Pubitemid 40460552)
45. Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H (2007) Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 55(3): 371-377. (Pubitemid 46331863)
46. Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE (2010) Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 12(1): 87-94.
47. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71(2): 105-113. (Pubitemid 46238939)
48. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4): 343-346. (Pubitemid 26342716)
49. Shih IM (1999) The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189(1): 4-11.
50. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
51. Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M (2013) Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem 288(13): 8991-9000.
52. Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW, Gratama JW (2008) Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost 100(4): 642-647.
53. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2): 244-285.
54. Travis WD BE, Müller-Hermelink HK, Harris CC (2004) WHO histological classification of tumors of the lung. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, p 342.
55. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117(2): 374-379. (Pubitemid 30111585)
56. Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, Smit EF (2010) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 102(2): 268-275.
57. Wang J, Xiao J, Wei X, Wang L, Lin L, Liu Z, Wang X, Sun B, Li K (2013) Circulating endothelial cells and tumor blood volume as predictors in lung cancer. Cancer Sci 104(4): 445-452.
58. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330(2): 150-162.
59. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11): 1359-1370.
60. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M (2003) Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361(9353): 206-210. (Pubitemid 36126220)
61. Yoneda K, Tanaka F, Kondo N, Orui H, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S (2012) Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM). Ann Surg Oncol 19(13): 4229-4237.
62. Zeng G, Cai S, Liu Y, Wu GJ (2012a) METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene 492(1): 229-238.
63. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X (2012b) CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109(4): 1127-1132.